⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3866607 | 0.75 | — | — | |
| SCHEMBL1988430 | 0.66 | — | — | |
| SCHEMBL18263937 | 0.66 | — | — | |
| SCHEMBL1186 | 0.62 | — | — | |
| SCHEMBL6060481 | 0.62 | — | — | |
| SCHEMBL11895919 | 0.59 | — | — | |
| SCHEMBL6167552 | 0.59 | — | — | |
| SCHEMBL7030384 | 0.56 | — | — | |
| SCHEMBL7030385 | 0.56 | — | — | |
| SCHEMBL406 | 0.53 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238324-A1 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240226131-A1 | 2'-CHLORO-2'-FLUORO-N2-AMINO-N6-METHYLAMINO PURINE NUCLEOTIDES FOR FLAVIVIRUS TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2024-07-11 | — | — | US | disclosed |
| EP-4395787-A1 | 2'-CHLORO-2'-FLUORO-N2-AMINO-N6 -METHYLAMINO PURINE NUCLEOTIDES FOR FLAVIVIRUS TREATMENT | ATEA Pharmaceuticals, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-118234499-A | 2 '-Chloro-2' -fluoro-N for use in flavivirus therapy2-Amino-N6Methylaminopurine nucleotides | 阿堤亚制药公司 | 2024-06-21 | — | — | CN | disclosed |
| US-11975016-B2 | 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment | Atea Pharmaceuticals, Inc. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20240002426-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2024-01-04 | — | — | US | disclosed |
| CN-112209980-B | substituted purine nucleotides | 阿堤亚制药公司 | 2023-12-05 | — | — | CN | disclosed |
| US-11813278-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-11-14 | — | — | US | disclosed |
| EP-4234565-A2 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | ATEA Pharmaceuticals, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11738038-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-9828410-B2 | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | Atea Pharmaceuticals, Inc. (US) | 2017-11-28 | — | — | US | disclosed |
| WO-2016144918-A1 | β-D-2'-DEOXY-2'α-FLUORO-2'-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2016-09-15 | — | — | WO | disclosed |
| US-20160257706-A1 | Beta-D-2'-DEOXY-2'-alpha-FLUORO-2'-beta-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2016-09-08 | — | — | US | disclosed |
| WO-2016014527-A2 | STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
| US-20160016986-A1 | STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT | ACHILLION PHARMACEUTICALS, INC. | 2016-01-21 | — | — | US | disclosed |
| US-20060124908-A1 | Modified conductive polymer and conductive member using the same | THE YOKOHAMA RUBBER CO., LTD. | 2006-06-15 | — | — | US | disclosed |
| EP-1670003-A1 | Modified conductive polymer and conductive element using the same | THE YOKOHAMA RUBBER CO., LTD. (JP) | 2006-06-14 | — | — | EP | disclosed |
| US-20040235761-A1 | Novel virus proliferaton inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1417967-A1 | NOVEL VIRUS PROLIFERATION INHIBITION/VIRUCIDAL METHOD AND NOVEL PYRADINE NUCLEOTIDE/PYRADINE NUCLEOSIDE ANALOGUE | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-05-12 | — | — | EP | disclosed |
| US-4002580-A | HALOGENATED POLYOLS AND PHOSPHORUS COMPOUNDS | GAF CORPORATION (US) | 1977-01-11 | — | — | US | disclosed |